Hosted on MSN18d
AbbVie to record $3.5B impairment charge for Cerevel drugAbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback